Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719632 | 0.98 | FAAH (0.68) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL24098140 | 0.98 | FAAH (0.68) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL15888717 | 0.98 | FAAH (0.68) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL13130099 | 0.94 | FAAH (0.56) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL24934994 | 0.93 | CASP2 (0.61) | FAAHEPHX1CASP2NAAATSHR | |
| SCHEMBL7786356 | 0.89 | FAAH (0.55) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL8537389 | 0.89 | FAAH (0.55) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL26280035 | 0.88 | FAAH (0.57) | FAAHEPHX1CASP2NAAAMEN1 | |
| SCHEMBL8326097 | 0.87 | TSHR (0.54) | FAAHEPHX1CASP2MEN1KMT2A | |
| SCHEMBL22856469 | 0.86 | MEN1 (0.68) | FAAHEPHX1CASP2NAAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050742-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4122925-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | Medshine Discovery Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10442756-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180201572-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-07-19 | — | — | US | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| US-20120220542-A1 | PEGYLATED C-PEPTIDE | CEBIX, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120178676-A1 | PEGYLATED C-PEPTIDE | CEBIX, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8178723-B2 | Process for preparing amides from alcohols and amines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-8178723-B2 | Process for preparing amides from alcohols and amines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-8178723-B2 | Process for preparing amides from alcohols and amines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-04-30 | — | — | US | disclosed |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-04-30 | — | — | US | disclosed |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220542-A1 | PEGYLATED C-PEPTIDE | LNPEP, NGLY1, PRCP | FAAH 2868/4885EPHX1 3802/4885CASP2 3612/4885 |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | ADH5, ADH1C, ADH1A | FAAH 673/4885EPHX1 4154/4885CASP2 2859/4885 |
| US-10442756-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | FAAH 3137/4885EPHX1 3059/4885CASP2 2639/4885 |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | ADH1A, ADH5, ADH1C | FAAH 80/4885EPHX1 1864/4885CASP2 4724/4885 |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | FAAH 2958/4885EPHX1 2758/4885CASP2 2176/4885 |
| US-20180201572-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | FAAH 3137/4885EPHX1 3059/4885CASP2 2639/4885 |
| US-20120178676-A1 | PEGYLATED C-PEPTIDE | LNPEP, NGLY1, PRCP | FAAH 2868/4885EPHX1 3802/4885CASP2 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.